Revenue from operations was at Rs 1,437.14 crore in Q3 FY24, up 8.69% from Rs 1,322.19 crore reported in the same quarter previous year.
Profit before tax stood at Rs 422.16 crore in the quarter ended December 2023, registering a growth of 26.08% on YoY basis.
On nine-month basis, the pharma company’s net profit grew 27.32% to Rs 914.16 crore on 10.1% rise in revenue from operations to Rs 4,410.28 crore in 9M FY24 over 9M FY23.
Abbott India has a portfolio of science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals.
The scrip hit an all time high at Rs 28,286.55 in today’s intraday session.